Anti-L-selectin monoclonal antibody - Stanford University

Drug Profile

Anti-L-selectin monoclonal antibody - Stanford University

Alternative Names: DREG 200 - Stanford University

Latest Information Update: 20 Feb 2008

Price : $50

At a glance

  • Originator Stanford University School of Medicine
  • Class
  • Mechanism of Action Advanced glycosylation end product modulators; L-selectin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Type 1 diabetes mellitus

Most Recent Events

  • 08 Apr 1999 No-Development-Reported for Type-1 diabetes mellitus in USA (Unknown route)
  • 23 Jan 1995 Preclinical development for Type-1 diabetes mellitus in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top